Could Ozempic Actually Be Making People Fatter? We’re Taking A Closer Look At This Controversial Weight Loss Drug
By now, most of us are familiar with Novo Nordisk’s new semaglutide injection Ozempic, but what many may not realize is that this drug actually has the potential to make patients unhealthier than they were before.
Ozempic (semaglutide) is a prescription injection manufactured by pharmaceutical giant Novo Nordisk. In late 2017, Ozempic became FDA-approved for the treatment of type 2 diabetes (also known as adult-onset diabetes), which is a chronic disease affecting over 37 million Americans. It then hit the market in early 2018 and became a blockbuster drug by the year’s end, meaning that Ozempic generated a minimum of $1 billion in annual sales. In 2020, Ozempic gained FDA approval for cardiovascular disease, making this the drug’s second approved indication. By the end of 2023, Ozempic is predicted to generate a total of $12.5 billion in sales. Its popularity has caused it to face supply chain challenges and shortages throughout 2022.